The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| WEED | -72.93% | -99.31% | -62.98% | -93% |
| S&P | +19.61% | +98.99% | +14.75% | +267% |
Canopy Growth Corp. engages in the production and sale of medical cannabis. The firm operates through the following segments: Global Cannabis and Other Consumer Products. The Global Cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Other Consumer Products segment encompasses the production, distribution and sale of consumer products by Storz & Bickel, This Works, BioSteel, and other ancillary revenue sources. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.
This Canadian pot company was the first to impress customers with cannabis derivatives, so what went wrong?
Aphria and Charlotte's Web Holdings are both outstanding long-term growth vehicles. Here's why.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $72.13M | 8.9% |
| Gross Profit | $12.57M | -26.0% |
| Gross Margin | 17.43% | -8.2% |
| Market Cap | $304.77M | -54.8% |
| Market Cap / Employee | $0.32M | 0.0% |
| Employees | 960 | -6.7% |
| Net Income | -$41.53M | 67.9% |
| EBITDA | -$8.19M | 20.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $126.20M | -34.3% |
| Accounts Receivable | $47.97M | 10.2% |
| Inventory | 93.8 | 11.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $308.88M | -46.6% |
| Short Term Debt | $18.92M | -58.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -47.15% | -12.5% |
| Return On Invested Capital | -70.83% | -10.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$11.64M | 79.1% |
| Operating Free Cash Flow | -$10.34M | 80.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.99 | 0.73 | 0.29 | 0.63 | -60.61% |
| Price to Sales | 2.02 | 1.57 | 0.76 | 1.15 | -52.83% |
| Price to Tangible Book Value | 1.35 | 1.00 | 0.38 | 0.87 | -61.75% |
| Enterprise Value to EBITDA | -86.43 | -80.42 | 58.78 | -60.41 | -44.61% |
| Return on Equity | -93.0% | -84.0% | -122.3% | -101.1% | 15.70% |
| Total Debt | $613.52M | $489.67M | $348.40M | $327.80M | -47.43% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
